Date: 09 Feb 2008
Hazard regression model and cure rate model in colon cancer relative survival trends: are they telling the same story?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Hazard regression models and cure rate models can be advantageously used in cancer relative survival analysis. We explored the advantages and limits of these two models in colon cancer and focused on the prognostic impact of the year of diagnosis on survival according to the TNM stage at diagnosis. The analysis concerned 9,998 patients from three French registries. In the hazard regression model, the baseline excess death hazard and the time-dependent effects of covariates were modelled using regression splines. The cure rate model estimated the proportion of ‘cured’ patients and the excess death hazard in ‘non-cured’ patients. The effects of year of diagnosis on these parameters were estimated for each TNM cancer stage. With the hazard regression model, the excess death hazard decreased significantly with more recent years of diagnoses (hazard ratio, HR 0.97 in stage III and 0.98 in stage IV, P < 0.001). In these advanced stages, this favourable effect was limited to the first years of follow-up. With the cure rate model, recent years of diagnoses were significantly associated with longer survivals in ‘non-cured’ patients with advanced stages (HR 0.95 in stage III and 0.97 in stage IV, P < 0.001) but had no significant effect on cure (odds ratio, OR 0.99 in stages III and IV, P > 0.5). The two models were complementary and concordant in estimating colon cancer survival and the effects of covariates. They provided two different points of view of the same phenomenon: recent years of diagnosis had a favourable effect on survival, but not on cure.
Remontet L, Esteve J, Bouvier AM, et al. Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publique 2003;51:3–30.PubMed
Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961;6:101–21.PubMed
Esteve J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of the net survival: elements for further discussion. Stat Med 1990;9:528–38.CrossRef
Hakulinen T, Tenkanen L. Regression analysis of relative survival rates. Appl Stat 1987;36:309–17.CrossRef
Boag JW. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J Roy Stat Soc B 1949;11:15–44.
Berkson J, Gage RP. Survival curves for cancer patients following treatment. J Am Stat Assoc 1952;47:501–15.CrossRef
World Health Organisation. International statistical classification of diseases and related health problems, tenth revision. Geneva: World Health Organisation 1992.
TNM classification of malignant tumours. 5th ed. New York: Wiley Inc.; 1997.
Bolard P, Quantin C, Abrahamowicz M, et al. Assessing time-by-covariate interactions in relative survival models using restrictive cubic spline functions. J Cancer Epidemiol Prev 2002;7:113–22.PubMed
Abrahamowicz M, MacKenzie T, Esdaile JM. Time-dependent hazard ratio: modelling and hypothesis testing with application in Lupus Nephritis. J Am Stat Assoc 1996;91:1432–9.CrossRef
Roncucci L, Fante R, Losi L, et al. Survival for colon and rectal cancer in a population-based cancer registry. Eur J Cancer 1996;32:295–302.CrossRef
- Hazard regression model and cure rate model in colon cancer relative survival trends: are they telling the same story?
European Journal of Epidemiology
Volume 23, Issue 4 , pp 251-259
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Cure rate model
- Hazard regression model
- Relative survival (RS)
- Time-dependent effect
- Industry Sectors
- Author Affiliations
- 1. Hospices Civils de Lyon, Service de Biostatistiques, Centre Hospitalier Lyon Sud, 69495, Pierre-Bénite, France
- 2. CNRS, UMR 5558 Equipe Biostatistique-Santé, Villeurbanne, 69100, France
- 3. Université Lyon 1, UMR 5558 Laboratoire Biostatistique-Santé, Villeurbanne, 69100, France
- 4. Registre des cancers digestifs, INSERM EMI 0106, Dijon, France
- 5. Université de Bourgogne, Dijon, France
- 6. CHU de Dijon, Dijon, France
- 7. Département des Maladies Chroniques et des Traumatismes, Institut de Veille Sanitaire, Saint-Maurice, France
- 10. CHU Caen, Caen, France
- 8. INSERM ERI3 ‘Cancers & Populations’, Caen, France
- 9. EA 3936 Université Caen, UF Epidémiologie—Pôle de Santé des Populations, Caen, France